Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Apr 24
ARS
2023 FY
Annual report to shareholders
6 Mar 24
DEFA14A
Additional proxy soliciting materials
6 Mar 24
DEF 14A
Definitive proxy
6 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Japanese Product Now Under Review for Nationwide Marketing Approval
26 Feb 24
PRE 14A
Preliminary proxy
23 Feb 24
8-K
Akili Announces Release Date for Fourth Quarter and Full Year 2023
21 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Dec 23
8-K
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
18 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Oct 23
8-K
Akili Announces Leadership Transition
6 Oct 23
EFFECT
Notice of effectiveness
29 Sep 23
POS AM
Prospectus update (post-effective amendment)
27 Sep 23
424B3
Prospectus supplement
13 Sep 23
8-K
Akili Announces Business Transformation, Focusing on Non-prescription Model
13 Sep 23
POS AM
Prospectus update (post-effective amendment)
5 Sep 23
424B3
Prospectus supplement
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
424B3
Prospectus supplement
10 Aug 23
8-K
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
424B3
Prospectus supplement
7 Jun 23
8-K
Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD
7 Jun 23
424B3
Prospectus supplement
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K/A
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
12 May 23
424B3
Prospectus supplement
11 May 23
8-K
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
424B3
Prospectus supplement
4 May 23
8-K
Submission of Matters to a Vote of Security Holders
4 May 23
424B3
Prospectus supplement
3 May 23
8-K
Regulation FD Disclosure
3 May 23
EFFECT
Notice of effectiveness
27 Mar 23
ARS
2022 FY
Annual report to shareholders
22 Mar 23
DEFA14A
Additional proxy soliciting materials
22 Mar 23
Latest ownership filings
4
Jacqueline Studer
12 Mar 24
4
Walter Edward Martucci II
12 Mar 24
4
Matthew Franklin
12 Mar 24
4
John Spinale
23 Feb 24
3
John Spinale
23 Feb 24
SC 13G/A
Cowen Aaron
13 Feb 24
SC 13G
Neuberger Berman Group LLC
12 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Jacqueline Studer
8 Dec 23
4
Santosh Shanbhag
8 Dec 23
4
Santosh Shanbhag
6 Nov 23
4
Jacqueline Studer
6 Nov 23
4
Walter Edward Martucci II
6 Nov 23
4
Matthew Franklin
13 Oct 23
4
Walter Edward Martucci II
6 Oct 23
SC 13D/A
Palihapitiya Chamath
6 Oct 23
4
Jacqueline Studer
14 Sep 23
4
Walter Edward Martucci II
14 Sep 23
4
Matthew Franklin
14 Sep 23
4
Santosh Shanbhag
14 Sep 23
4
Santosh Shanbhag
4 May 23
4
WILLIAM A JONES JR
4 May 23
4
Kenneth Ehlert
4 May 23
4
Jacqueline Studer
4 May 23
4
Walter Edward Martucci II
4 May 23
4
Christine Lemke
4 May 23
4
Chamath Palihapitiya
4 May 23
4
Mary Hentges
4 May 23
4
Walter Edward Martucci II
14 Mar 23
4
Jacqueline Studer
14 Mar 23
4
Matthew Franklin
14 Mar 23
4
Santosh Shanbhag
14 Mar 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
Cowen Aaron
13 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
MILLENNIUM MANAGEMENT LLC
7 Feb 23
SC 13G
BAILLIE GIFFORD & CO
20 Jan 23
3/A
Kenneth Ehlert
13 Dec 22
3/A
Anil Jina
13 Dec 22
3/A
Jonathan David
13 Dec 22